medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 4

<< Back Next >>

Ann Hepatol 2017; 16 (4)

Isolated Intrapulmonary Vascular Dilatations and the Risk of Developing Hepatopulmonary Syndrome in Liver Transplant Candidates

Mendizabal M, Goldberg DS, Piñero F, Arufe DT, de la Fuente MJ, Testa P, Coronel M, Baratta S, Podestá LG, Fallon MB, Silva MO

Language: English
References: 16
Page: 548-554
PDF size: 158.36 Kb.


ABSTRACT

Background. The natural history of intrapulmonary vascular dilations (IPVD) and their impact on patient outcomes in the setting of portal hypertension has only been described in small series. Aims. To assess the development of hepatopulmonary syndrome (HPS) in patients with isolated IPVD and to evaluate outcomes of IPVD and HPS among patients evaluated for liver transplantation (LT). Material and methods. Data from a prospective cohort of patients evaluated for LT with standardized screening for HPS were analyzed. IPVDs were defined as the presence of microbubbles in the left atrium › 3 cycles following right atrial opacification. HPS was defined as the presence of IPVD and hypoxemia (Alveolar-arterial gradient ≥ 15 mmHg) in the absence of concomitant cardiopulmonary disease. Results. A total of 104 patients with negative contrast-enhanced echocardiogram (CE) were compared to 63 patients with IPVD and 63 patients with HPS. Only four patients were categorized as ‘severe’ HPS based on degree of hypoxemia (defined as PaO2 ‹ 60 mmHg). Twenty IPVD patients were followed with ABG over a mean duration of 21 months (range 9- 43), of whom 7 (35%) subsequently met HPS criteria. Overall unadjusted survival from the time of LT evaluation using multi-state survival models that accounted for pre- and post-LT time was not statistically different among the three groups (negative CE, IPVD, and HPS; p › 0.5). Conclusions. Patients with IPVD appear to have a substantial risk of developing oxygenation impairment over time and progress to HPS. In our cohort, survival in patients with HPS and isolated IPVD is not different when compared to those without IPVDs.


REFERENCES

  1. Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB, ERS Task Force Pulmonary-Hepatic Vascular Disorders PHD Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-80.

  2. Arguedas MR, Singh H, Faulk DK, Fallon MB. Utility of Pulse Oximetry Screening for Hepatopulmonary Syndrome. Clin Gastroenterol Hepatol 2007; 5: 749-54.e1.

  3. Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, Saha VH, et al. Impact of Hepatopulmonary Syndrome on Quality of Life and Survival in Liver Transplant Candidates. Gastroenterology 2008; 135: 1168-75.

  4. Pascasio JM, Grilo I, López-Pardo FJ, Ortega-Ruiz F, Tirado JL, Sousa JM, Rodriguez-Puras MJ, et al. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant 2014; 14: 1391-9.

  5. Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Müller C. Prognostic significance of the hepatopul- monary syndrome in patients with cirrhosis. Gastroenterology 2003; 125: 1042-52.

  6. Kochar R, Tanikella R, Fallon MB. Serial Pulse Oximetry in Hepatopulmonary Syndrome. Dig Dis Sci 2011; 56: 1862-8.

  7. Gupta S, Nayyar D, Pomier-Layrargues G. Variability of Oxygenation in Possible Hepatopulmonary Syndrome: Effects of Requiring Two Abnormal Arterial Blood Gas Results for Diagnosis. Dig Dis Sci 2015; 60: 1848-55.

  8. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, and STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.

  9. Krowka MJ. Management of Pulmonary Complications in Pretransplant Patients. Clin Liver Dis 2011; 15: 765-77.

  10. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MAE, Sitbon O, et al.: International Liver Transplant Society Practice Guidelines. Transplantation 2016; 100: 1440-52.

  11. Kanber GJ, King FW, Eschar YR, Sharp JT. The alveolar-arterial oxygen gradient in young and elderly men during air and oxygen breathing. The American Review of Respiratory Disease 1968; 97: 376-81.

  12. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology (Baltimore, Md) 2005; 41: 1122-9.

  13. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, Müller C: Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002; 51: 853-9.

  14. Roberts KE, Kawut SM, Krowka MJ, Brown RS, Trotter JF, Shah V, Peter I, et al. Genetic Risk Factors for Hepatopulmonary Syndrome in Patients With Advanced Liver Disease. Gastroenterology 2010; 139: 130-9.e24.

  15. Agarwal PD, Hughes PJ, Runo JR, Ibrisim D, Lucey MR, Said A. The clinical significance of intrapulmonary vascular dilations in liver transplant candidates. Clin Transplant 2012; 27: 148-53.

  16. Gupta S, Castel H, Rao RV, Picard M, Lilly L, Faughnan ME, Pomier-Layrargues: Improved Survival After Liver Transplantation in Patients with Hepatopulmonary Syndrome. Am J Transplant 2010; 10: 354-63.




2020     |     www.medigraphic.com